Objective measurement and clinical significance of TILs in non-small cell lung cancer.

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. JAMA Oncol (2016) 2.79

Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res (2015) 1.77

Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer. J Clin Oncol (2016) 0.99

Biomarker development in the precision medicine era: lung cancer as a case study. Nat Rev Cancer (2016) 0.89

Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer. Oncotarget (2016) 0.86

Quantitative assessment of the spatial heterogeneity of tumor-infiltrating lymphocytes in breast cancer. Breast Cancer Res (2016) 0.81

The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma. Oncotarget (2016) 0.81

PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC. PLoS One (2016) 0.80

CD45RO(+) Memory T Lymphocytes - a Candidate Marker for TNM-Immunoscore in Squamous Non-Small Cell Lung Cancer. Neoplasia (2015) 0.80

Focus on Nivolumab in NSCLC. Front Med (Lausanne) (2016) 0.78

Tumor infiltrating lymphocytes in lung cancer: a new prognostic parameter. J Thorac Dis (2016) 0.78

Moving towards a customized approach for drug development: lessons from clinical trials with immune checkpoint inhibitors in lung cancer. Transl Lung Cancer Res (2015) 0.77

Importance of tumor infiltrating lymphocytes in non-small cell lung cancer? Ann Transl Med (2016) 0.77

The presence of intraepithelial CD45RO+ cells in resected lymph nodes with metastases from NSCLC patients is an independent predictor of disease-specific survival. Br J Cancer (2016) 0.76

Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. Eur J Nucl Med Mol Imaging (2016) 0.76

Analysis of the immune microenvironment in resected non-small cell lung cancer: the prognostic value of different T lymphocyte markers. Oncotarget (2016) 0.76

HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival. Sci Rep (2016) 0.76

A randomized phase II study of radiation induced immune boost in operable non-small cell lung cancer (RadImmune trial). BMC Cancer (2015) 0.75

Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions. Oncotarget (2016) 0.75

What does the future hold for immunotherapy in cancer? Ann Transl Med (2016) 0.75

HHLA2, a new immune checkpoint member of the B7 family, is widely expressed in human lung cancer and associated with EGFR mutational status. Clin Cancer Res (2016) 0.75

Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients. Oncoimmunology (2016) 0.75

Tumor lymphocytic infiltration in non-small cell lung cancer: the ultimate prognostic marker? Transl Lung Cancer Res (2016) 0.75

Predictive value of peripheral regulatory T cells in non-small cell lung cancer patients undergoing radiotherapy. Oncotarget (2017) 0.75

The Prognostic Value of Tumor-infiltrating Lymphocytes in Hepatocellular Carcinoma: a Systematic Review and Meta-analysis. Sci Rep (2017) 0.75

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Adv Anat Pathol (2017) 0.75

Heterogeneity of CD8(+) tumor-infiltrating lymphocytes in non-small-cell lung cancer: impact on patient prognostic assessments and comparison of quantification by different sampling strategies. Cancer Immunol Immunother (2016) 0.75

The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer (2012) 24.94

The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90

PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature (2014) 10.39

Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med (2002) 8.04

Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest (2013) 4.96

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res (2013) 3.48

Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol (2014) 3.21

Cancer classification using the Immunoscore: a worldwide task force. J Transl Med (2012) 2.88

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med (2011) 2.86

In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res (2014) 2.68

Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res (2008) 2.37

CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest (2013) 2.18

Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer (2006) 2.09

CD4+ T cells in cancer stroma, not CD8+ T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci (2003) 1.78

Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. J Clin Oncol (2008) 1.61

Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. Clin Cancer Res (2014) 1.36

Harnessing the immune system for the treatment of non-small-cell lung cancer. J Clin Oncol (2013) 1.22

Increased levels of tumor-infiltrating lymphocytes are associated with improved recurrence-free survival in stage 1A non-small-cell lung cancer. J Surg Res (2011) 1.20

Density of tumor-infiltrating lymphocytes correlates with disease recurrence and survival in patients with large non-small-cell lung cancer tumors. J Surg Res (2009) 1.07

Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res (2014) 1.07

Infiltration of CD8+ T cells in non-small cell lung cancer is associated with dedifferentiation of cancer cells, but not with prognosis. Tohoku J Exp Med (2000) 1.00

A high number of CD8+ T cells infiltrated in NSCLC tissues is associated with a favorable prognosis. Appl Immunohistochem Mol Morphol (2010) 0.94